The board and management consists of experienced scientific and commercialization executives with decades of experience in the ophthalmic sector. The company also benefits from the strategic direction provided by world leaders in ophthalmology.


Currently funding is provided by investments from the founders as well as funding from the Connecticut Innovation Fund.